HUTCHMED (China) Limited (HCM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HUTCHMED (China) Limited
(“HUTCHMED” or the “Company”) (NASDAQ: HCM). Investors who purchased HUTCHMED securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether HUTCHMED and certain of its officers and/or directors have violated federal securities laws.
On May 2, 2022, HUTCHMED announced that the U.S. Food and Drug Administration (FDA) rejected its application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required. Following this news, HUTCHMED's American depositary share (ADS) price dropped $2.86 per share, or 18%, to close at $12.23 on May 2, 2022.
If you are aware of any facts relating to this investigation or purchased HUTCHMED shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.